Q-Med reports strong first quarter

Q-MED REPORTS A STRONG FIRST QUARTER *Revenues increased by 111% to SEK 30.0 million (14.2). *Income after financial items amounted to SEK 6.2 (1.5) million. Income for *1999 includes extraordinary revenues of SEK 2.2 million. ® *Launch of Deflux , a product registered in December 1998. *Restylane approved for the Australian market. *New Managing Director - Per-Olof Wallström, from Bristol Myers Squibb ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/04/20/19990420BIT00370/bit0001.doc The full report http://www.bit.se/bitonline/1999/04/20/19990420BIT00370/bit0002.pdf The full report